Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | FPR2 | P25090 | 4/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7092625 | 0.87 | HRH4 (0.53) | KMT2AMEN1HRH4AKR1C3FPR2 | |
| Formic Acid SCHEMBL7574159 | 0.86 | KMT2A (0.56) | KMT2AMEN1HRH4AKR1C3NPC1 | |
| SCHEMBL7243123 | 0.86 | HRH4 (0.59) | HRH4AKR1C3DRD3DRD2HRH3 | |
| SCHEMBL7091254 | 0.82 | ADRB3 (0.66) | DRD3DRD2 | |
| SCHEMBL7569026 | 0.77 | ADRB3 (0.51) | KMT2AMEN1AKR1C3DRD3DRD2 | |
| SCHEMBL7092875 | 0.77 | ALDH1A1 (0.56) | KMT2AMEN1MAPT | |
| SCHEMBL7096591 | 0.76 | HRH4 (0.56) | KMT2AMEN1HRH4AKR1C3FPR2 | |
| SCHEMBL7092879 | 0.76 | PKM (0.53) | KMT2AMEN1HRH3 | |
| SCHEMBL9410569 | 0.75 | HRH4 (0.74) | KMT2AMEN1HRH4AKR1C3NPC1 | |
| SCHEMBL7097003 | 0.75 | PLCG2 (0.57) | KMT2AHRH4NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | KMT2A 3613/4885MEN1 2931/4885HRH4 242/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | KMT2A 4020/4885MEN1 2107/4885HRH4 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.